Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models.

McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, Schoch KM, Hoye ML, Shabsovich M, Sun L, Luo Y, Zhang M, Comfort N, Wang B, Amacker J, Thankamony S, Salzman DW, Cudkowicz M, Graham DL, Bennett CF, Kordasiewicz HB, Swayze EE, Miller TM.

J Clin Invest. 2018 Aug 1;128(8):3558-3567. doi: 10.1172/JCI99081. Epub 2018 Jul 16.

2.

Erratum: The Non-Coding RNA Journal Club: Highlights on Recent Papers-4. Non-Coding RNA 2016, 2, 9.

Gautheret D, Taube JH, Mani SA, Santulli G, Cuerda-Gil D, Slotkin RK, Zhang B, Wang Y, Salzman DW, Weidhaas JB.

Noncoding RNA. 2016 Sep 30;2(4). pii: E10. doi: 10.3390/ncrna2040010.

3.

The Non-Coding RNA Journal Club: Highlights on Recent Papers-4.

Gautheret D, Taube JH, Mani SA, Santulli G, Cuerda-Gil D, Slotkin RK, Zhang B, Wang Y, Salzman DW, Weidhaas JB.

Noncoding RNA. 2016 Sep 21;2(3). pii: E9. doi: 10.3390/ncrna2030009.

4.

miR-34 activity is modulated through 5'-end phosphorylation in response to DNA damage.

Salzman DW, Nakamura K, Nallur S, Dookwah MT, Metheetrairut C, Slack FJ, Weidhaas JB.

Nat Commun. 2016 Mar 21;7:10954. doi: 10.1038/ncomms10954.

5.

Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.

McVeigh TP, Jung SY, Kerin MJ, Salzman DW, Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, Pilarski R, Telesca D, Slack FJ, Weidhaas JB.

Cell Cycle. 2015;14(13):2091-9. doi: 10.1080/15384101.2015.1041694. Epub 2015 May 11.

6.

A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.

Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S.

Clin Cancer Res. 2014 Sep 1;20(17):4499-4510. doi: 10.1158/1078-0432.CCR-14-0348.

7.

A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer.

Dorairaj JJ, Salzman DW, Wall D, Rounds T, Preskill C, Sullivan CA, Lindner R, Curran C, Lezon-Geyda K, McVeigh T, Harris L, Newell J, Kerin MJ, Wood M, Miller N, Weidhaas JB.

BMC Cancer. 2014 Jun 10;14:421. doi: 10.1186/1471-2407-14-421.

8.

SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer.

Salzman DW, Weidhaas JB.

Pharmacol Ther. 2013 Jan;137(1):55-63. doi: 10.1016/j.pharmthera.2012.08.016. Epub 2012 Sep 3. Review.

9.

miRNAs in the spotlight: Making 'silent' mutations speak up.

Salzman DW, Weidhaas JB.

Nat Med. 2011 Aug 4;17(8):934-5. doi: 10.1038/nm0811-934. No abstract available.

PMID:
21818091
10.

The 5' terminal uracil of let-7a is critical for the recruitment of mRNA to Argonaute2.

Felice KM, Salzman DW, Shubert-Coleman J, Jensen KP, Furneaux HM.

Biochem J. 2009 Aug 13;422(2):329-41. doi: 10.1042/BJ20090534.

11.

P68 RNA helicase unwinds the human let-7 microRNA precursor duplex and is required for let-7-directed silencing of gene expression.

Salzman DW, Shubert-Coleman J, Furneaux H.

J Biol Chem. 2007 Nov 9;282(45):32773-9. Epub 2007 Aug 27.

Supplemental Content

Loading ...
Support Center